← Back to Search

Tyrosine Kinase Inhibitor

Jaktinib for Myelofibrosis

Phase 1
Recruiting
Research Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Expected life expectancy is greater than 24 weeks.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at least 24 weeks, up to approximately 1 year
Awards & highlights

Study Summary

This trial is testing whether Jaktinib can shrink the size of the spleen and improve symptoms in people with myelofibrosis.

Who is the study for?
This trial is for adults over 18 with myelofibrosis who haven't responded well to standard treatments. They should be relatively stable (ECOG PS 0, 1, or 2) and expected to live more than 24 weeks. Pregnant or breastfeeding women can't join, nor those planning pregnancy without effective contraception.Check my eligibility
What is being tested?
The study is testing Jaktinib Hydrochloride Tablets as a new treatment option for Myelofibrosis. It's aimed at patients who have not had success with existing FDA-approved JAK inhibitors.See study design
What are the potential side effects?
While the specific side effects of Jaktinib are not listed here, similar drugs often cause issues like dizziness, headaches, nausea, low blood counts leading to increased infection risk or bleeding problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are expected to live for more than 24 weeks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at least 24 weeks, up to approximately 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and at least 24 weeks, up to approximately 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose-limiting toxicities (DLTs) of jaktinib hydrochloride tablets
Safety of jaktinib hydrochloride tablets
Secondary outcome measures
Efficacy of jaktinib hydrochloride tablets
Tablet Dosage Form

Trial Design

1Treatment groups
Experimental Treatment
Group I: JaktinibExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Suzhou Zelgen Biopharmaceuticals Co.,LtdLead Sponsor
64 Previous Clinical Trials
8,349 Total Patients Enrolled

Media Library

Jaktinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05279001 — Phase 1
Myelofibrosis Research Study Groups: Jaktinib
Myelofibrosis Clinical Trial 2023: Jaktinib Highlights & Side Effects. Trial Name: NCT05279001 — Phase 1
Jaktinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05279001 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have been enrolled in this clinical research project?

"That is correct. The clinicaltrials.gov registry indicates that this research endeavour, initially posted on July 1st 2022, has commenced the recruitment process. 26 participants are being sought from a single site for the trial."

Answered by AI

Has Jaktinib Hydrochloride Tablet been granted clearance by the FDA?

"Due to the limited amount of data available on Jaktinib Hydrochloride Tablet's safety and efficacy, our team has assigned it a score of 1."

Answered by AI

Are there any open spots for individuals to take part in the experiment?

"Affirmative. Clinicaltrials.gov confirms that this research project, which went live on July 1st 2022 is actively seeking volunteers. Only 26 participants are needed and the study will be conducted at a single site."

Answered by AI
~17 spots leftby May 2025